Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J06BD10

Enflonsia(clesrovimab)

Respiratory Syncytial Virus Vaccines

Marketing Authorisation Holder: Merck Sharp Dohme Limited

EMA Authorisation: 15/04/2026

INN: clesrovimab

Indication

Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Enflonsia — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.